EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study

Takeshi Honda, Kei Morikawa, Saori Takata, Hisashi Tanaka, Hidetoshi Itani, Kazuya Horiuchi, Ichiro Kawada, Hideyuki Nakagawa, Yoshiro Nakahara, Yoshitaka Seki, Akihiro Bessho, Nobumasa Takahashi und 19 weitere

Therapeutic Advances in Medical Oncology · 2026-11 · 18

DOI: 10.1177/17588359261476047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 03.11.2026. Verfasst von Takeshi Honda und 30 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAKENHI, Tohoku Medical Megabank Project of the Ministry of Education, Culture, Sports, Science, and Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While EGFR tyrosine kinase inhibitors (TKIs) like afatinib are standard treatments for EGFR-mutated non-small cell lung cancer (NSCLC), predicting which patients will achieve durable responses remains challenging. Given the emergence of more toxic and costly combination therapies, identifying candidates who can achieve long-term survival with TKI monotherapy is a critical clinical priority.

Objectives

To identify baseline plasma and extracellular vesicle (EV) metabolomic biomarkers that predict progression-free survival (PFS) and overall survival (OS) in patients treated with first-line afatinib.

Design

A prospective, multicenter, single-arm observational biomarker discovery study (the EXTRA study).

Methods

We enrolled 103 patients with advanced or recurrent EGFR-mutated NSCLC. Fasting plasma (n = 101 evaluable) and EV (n = 99 evaluable) samples collected at baseline were subjected to comprehensive metabolomic profiling (630 metabolites) using the MxP® Quant 500 kit (Biocrates Life Sciences AG, Innsbruck, Austria) combined with UHPLC-MS/MS. Durable response was defined as a progression-free survival (PFS) of 18 months or longer. Associations with PFS and OS were evaluated using false discovery rate (FDR)-adjusted univariable Cox models and validated via bootstrap resampling.

Results

In this first large-scale concurrent analysis, baseline EV metabolites unexpectedly showed no significant correlation with survival end points. Conversely, baseline plasma metabolites provided robust predictive signatures. Histidine and five lysophosphatidylcholines (LPC16:0, 17:0, 18:0, 18:1, 18:2) were identified as significant positive predictors of PFS. For OS, one phosphatidylcholine (PC ae C30:1) and four amino acids (homoarginine, histidine, threonine, tryptophan) were positive predictors, while one dihydroceramide (Cer [d18:1/24:1]) was a negative predictor. Prognostic scores based on these metabolites successfully stratified patients into three risk groups with significantly distinct survival outcomes (p < 0.001).

Conclusion

Plasma-derived, but not EV-derived, metabolomic signatures accurately predict durable response and survival in EGFR-mutated NSCLC treated with afatinib. These novel biomarkers reflect host immunity and tumor microenvironment states, offering a step toward precision medicine by identifying patients likely to benefit from monotherapy over intensive combination regimens. Registration University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_his_list.cgi?recptno=R000028688 (UMIN000024935).

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAKENHI
  • Tohoku Medical Megabank Project of the Ministry of Education
  • Culture, Sports, Science, and Technology
  • Japan Agency for Medical Research and Development

Zitieren

APA

Honda, T., Morikawa, K., Takata, S., Tanaka, H., Itani, H., Horiuchi, K., Kawada, I., Nakagawa, H., Nakahara, Y., Seki, Y., Bessho, A., Takahashi, N., Hayashi, K., Endo, T., Takeyama, K., Maekura, T., Takigawa, N., Kawase, A., Endoh, M., …, & Saigusa, D. (2026). Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261476047

Vancouver

Honda T, Morikawa K, Takata S, Tanaka H, Itani H, Horiuchi K, et al. Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261476047

BibTeX
@article{Honda2026,
  author = {Honda, Takeshi and Morikawa, Kei and Takata, Saori and Tanaka, Hisashi and Itani, Hidetoshi and Horiuchi, Kazuya and Kawada, Ichiro and Nakagawa, Hideyuki and Nakahara, Yoshiro and Seki, Yoshitaka and Bessho, Akihiro and Takahashi, Nobumasa and Hayashi, Kentaro and Endo, Takeo and Takeyama, Kiyoshi and Maekura, Toshiya and Takigawa, Nagio and Kawase, Akikazu and Endoh, Makoto and Nemoto, Kenji and Kishi, Kazuma and Fukuuchi, Tomoko and Iwasaki, Yuko and Soejima, Kenzo and Okuma, Yusuke and Togashi, Akira and Ueda, Koji and Yoshimura, Kenichi and Matsutani, Noriyuki and Seki, Nobuhiko and Saigusa, Daisuke},
  title = {Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261476047}
}
Kostenlos starten →